The Division of Rheumatology strives to understand more about rheumatoid arthritis (RA) through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
| Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
StopRA:National 24-1080 Kevin Deane, MD/PhD Christopher Striebich, MD/PhD | StopRA:National is a study being conducted by The Autoimmune Disease Prevention Center (ADPC) at the University of Colorado and designed to follow people who are at-risk of developing RA based on having a positive anti-CCP test, but without a diagnosis of RA. The goal of StopRA:National is to create opportunities for anti-CCP+ individuals without clinical RA to participate in research to help us learn more about RA development, and ultimately how to prevent RA. | Individuals who over the age of 18, with a positive CCP blood test without a diagnosis of RA | 303-724-0945 To learn more, visit our website: StopRA:National for Providers |
Interdisciplinary Joint Biology Program for Rheumatic and Orthopedic Diseases 20-1908 Larry Moreland, MD | The goal of the University of Colorado Interdisciplinary Joint Biology Program is to employ cutting edge science and technology to advance the research of inflammatory, degenerative and musculoskeletal joint diseases. | Individuals with RA, SpA, PsA, AS, OA or any other form of inflammatory arthritis with active disease in their elbow, wrist, hand joints, knee, ankle or shoulder and are willing to undergo a synovial biopsy at that site or individuals who are having an orthopedic surgery and are willing to donate their tissues that would normally be discarded | 303-724-7541
Or visit |
AMP-AIM 23-0022 Larry Moreland, MD | An observational study to better understand joint destruction in patients with autoimmune disorders like rheumatoid arthritis and develop new treatments | We are recruiting individuals who are newly diagnosed with rheumatoid arthritis and have a swollen knee or wrist | 303-724-7541
|
Sonoma Biotherapeutics 22-1945 Larry Moreland, MD | A clinical trial of chimeric antigen receptor (CAR) T cell therapy, which is a relatively new therapeutic approach that uses a patient's own immune cells to treat their rheumatoid arthritis | Individuals with moderate to severe rheumatoid arthritis that is not well managed by their current medication and who have a swollen knee or wrist. | 303-724-8784
|
AMG 20240033 25-0339 Larry Moreland, MD | A Phase 2a, Open-label clinical trial assessing the safety, tolerability, and efficacy of Blinatumomab in Active Refractory Rheumatoid Arthritis | Individuals with moderate to severe rheumatoid arthritis despite past treatment with multiple RA medications | 303-724-8784 |
STARS-ILD 25-1951 Melissa Griffith, MD | Observational study investigating the causes of Interstitial Lung Disease (ILD) in people with Rheumatoid Arthritis (RA) and Scleroderma (SSc). | Basic Eligibility Criteria: - Confirmed diagnosis of RA or Ssc, with or without ILD. - Willingness to take pulmonary function tests, sputum collection, and complete a CT scan. | 303-724-7594 |
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.